I am a retired computer scientist (HP) and am enjoying researching new medical treatments and the associated companies. I believe that carefully understanding and researching the underlying science will help understand the chance for success of clinical trials (side effects and key factors like delivery for mRNA).
Expert Consultant in biotechnology, intellectual property, patents, molecular genetics, genomics, gene regulation, RNA silencing, RNA interference, epigenetics
Editor in Chief, Frontiers in Plant Genetics and Genomics
Professor Emeritus at University of Arizona, School of Plant Sciences, College of Agricultural and Life Sciences, Tucson, Arizona
Individual Investor with a preference for long-term value-oriented investments that are based on in-depth research & understanding of the company's products and markets. Educational background includes mechanical engineering and MBA (Finance) degrees.
I come from a background of Electrical Engineering. I enjoyed the creativity of working in the high-tech industry for 24 years, in design and managerial positions. In 2013 I decided to take a few years off from high-tech work, and concentrate on other areas of interest, including investing and stock analysis. I mostly invest in technology, and biotech, which I believe is the next revolution that is already underway, like computers were 20-50 years ago.
I hold a PhD in Electrical Engineering (Control Theory) from Stanford University and a Masters Degree in Engineering-Economic Systems (now called Management Science and Engineering at Stanford).
I have been fascinated by the stock market since I was 14 (that is 37 years ago at writing). It has always struck me as the place to be.
In the last 10+ years I moved from what I would call the "herd mentality" to a more educated process. In particular, my years as a Principal Software Engineer in a derivatives software development company, interacting closely with Financial Engineers, showed me clearly the simple science behind this: "Mean Reversion is All We Know about the Game!"
Long-time individual investor who began trading in mid-90's. My philosophy is to identify "value gaps" between what I believe a company to be worth today versus it's stock price. I do not follow charts or technicals, but rather look to find companies with stock prices that move out of sync with the value of recent news to find and (hopefully) capitalize on these value gaps.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
Founder of Slingshot Insights, a company that works to provide retail investors access to professional grade investment research tools not readily at their disposal. As a former analyst at a large hedge fund, I found that as I began trading individual stocks on my own, I missed the research tools available to me when I worked for a large institution. The company was born from this idea and my desire to have access to a resource like SI.
www.SlingshotInsights.com Join for free today and check out our cartoon where "Investor Man" Becomes the Smart Money (and explains what Slingshot Insights can do for your diligence process)
Prior to starting Slingshot Insights, I was an analyst at a large hedge fund where I focused on the pharmaceutical industry creating investment theses driven by primary research. I remain a very active investor in a variety of stocks.
I am a financial adviser and Registered Investment Adviser specializing in emerging growth stocks. I am also a market technician with an article written in the Wall Street Journal about one of my market hedging techniques (Google: Moving The Market-Tracking The Numbers, Edward Levi, The Wall Street Journal). I've spent 11 years at Dean Witter, 18 at Smith Barney, and 8 at Morgan Stanley. I've decided to join Beverly Hills Wealth Management so that I can concentrate on building private hedge fund portfolios for clients, whether related to growth or income, or both.
I specialize in emerging growth investments that run the gamut from medical devices and therapies, technology, and alternative energy.
I've spent a lifetime of research in the technical aspects of the market, measuring market sentiment, momentum, and chart patterns. For many years I've given market presentations to financial advisers at Smith Barney and Morgan Stanley showing extremes in sentiment and chart patterns. I have my own proprietary indicators that measure extremes and hedge clients portfolios at times when protection is in order. My goal is to be fully invested in the rising trends but very protective of portfolios when sentiment and momentum indicators reach extremes. I'm usually early in predicting trends but usually right. Extreme sentiment is a leading indicator, and I believe it precludes market and economic fundamentals as a source of knowledge of changing trends.
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
Private investment analyst and writer with an interest in companies with emerging technologies oriented towards improving healthcare, alternative investments, emerging markets, and technology.
Keith began his career as a research scientist (developmental biology, biochemistry, molecular biology) at the Australian National University, University of Oxford (UK), the Max Planck Institute for Biochemistry (Munich, Germany) and finally Macquarie University (Sydney) where he held a Chair in Biology and established the Centre for Analytical Biotechnology. Pioneering the area of proteomics (with Marc Wilkins in his group coining the term), Keith established the world’s first government-funded Major National Proteomics Facility (Australian Proteome Analysis Facility) which was involved with industrialising protein science.
Keith left academe with his team to found Proteome Systems Ltd in 1999 to commercialise proteomics. The company had a strong focus on intellectual property, engineering/technology and bioinformatics. As CEO he led the company to ASX listing in 2004. Since 2005 Keith has been involved in new business development in biotech, e-health and other emerging technologies. Keith sees climate change and sustainable development as a major issue for humankind and also a major business disruptor/risk and opportunity.
Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering.
With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. He is not a financial advisor but his perspective adds relevance to decision-making concerning feasibility and investment in technology innovation.
I am an individual and occasional investor with a passion for biotechnology and stocks. I am working as an engineer with ties to the healthcare sector.
I build investment theses based on thorough personal research and end up picking only stocks that I think hold a very high and long-term potential. I specialize in micro-cap and/or European biotechs, tracking undervalued opportunities and basing my investment choices on the deep analysis of a company's fundamentals and its long-term perspective (at least several years).
Follow me on twitter: https://twitter.com/Logribel
My name is Dr Kanak Kanti De, MBBS, MD, PhD, retired medical practitioner, cancer survivor, healthcare sector investor, over 30 years' experience in the sector both in India and the United States. I write/have written on Motley Fool, SeekingAlpha, Benzinga, and on Forbes. I am consistently ranked high on TipRanks, although I don't like their ranking system. My portfolio has consistently beat the various indices for years. Email me to discuss my articles, or for just an adda (Bengali for informal chat) email@example.com.
Spent my entire 28 year career on Wall Street with over a decade at Bear Stearns. No "Wall Street Titan" in real life but WST is an alias that I've used for years on Yahoo so I use it when I write on SA. I have gained a significant amount of knowledge regarding the stem cell sector over the years and have recently launched a premium service covering this exciting area.
I am an engineer and long time technical consultant specializing in control and instrumentation systems for medical, industrial, vehicle and aerospace companies. The technical, cultural, market, regulatory and other factors that separate successful products and companies from their peers has fascinated me for many years. My investment experience is limited to my own accounts.
I am a retired accountant with a background in large mining projects from feasibility to full-scale operation.
I manage my own investments and for the majority of my portfolio I have a strong preference for Blue Chip stocks.
For the balance of my portfolio I have an interest in small and micro-cap stocks, seeking superior returns.I seek alpha returns through identifying companies with the right fundamentals and assessing the risks and investing long. Although investing long, I understand the importance of share price in the short to medium term for these small cap companies as it impacts their ability to raise capital.
Whether you are a large or small firm, GeoInvesting will cater to your needs and create a sound process for corporate diligence. Our specialty is Portfolio Protection – in fact, every aspect of what we do boils down to various ways that your M&A process or investment portfolio can be safeguarded against red flags.
To accomplish this we choose to work closely with you so you can be kept abreast of the progress of our due diligence from start to finish, making sure that we cultivate a relationship of trust between our team and yours.
Who Can We Help Specifically?
We actually do not limit ourselves to any specific group? We have worked at great lengths with:
>High Net Worth Investors
>Private & Public M&A
>Other Due Diligence Firms
There is really no one that we can’t work with since we’ve covered just about every facet of the due diligence process, whether it be on-the-ground or “through the files.” We can even tailor our services to your specific requirements.
We have a retail solution for everyone – the long investor, the short investor, the pump and dump investor and the every day trader that is interested in the micro cap arena. We’ve shown that we can overcome the challenges posed by any market environment, quickly seizing investment and trading opportunities as they arise. Because of this, our Premium members have been able to enjoy above-average returns on our ideas. Our solutions enable us to cater to what matters to you the most.
Do you want access to reports that can convey the proper valuation of equities, reports that can immediately convince the market that these valuations are warranted? Do you want information arbitrage that allows you to be among the first to take action based on the intel? Do you need daily ideas, some of which have proven to be some of the most rewarding calls to action that the GeoTeam has offered? Would you like to follow our GeoBargains and select trades? Or do you just need to be part of an exclusive twitter following that receives alerts before the rest of the market?
If you have answered yes to any of the questions above, then don’t wait any longer. Join our Network and see why our following continues to grow on a daily basis. The faster you join, the more likely you will be among the first to harness the power of our offering.
Sign up today and start to get:
>Daily Trading Ideas
See GeoInvesting Prime on Seeking Alpha Marketplace